Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    CA220-007
Show Display Options
Rank Status Study
1 Completed Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
Condition: Melanoma
Interventions: Biological: BMS-982470 (recombinant interleukin-21);   Biological: Ipilimumab

Indicates status has not been verified in more than two years